The impact of corticosteroid therapy on clinical outcomes in paediatric deep neck space infections: A meta-analysis.

Int J Pediatr OtorhinolaryngolAug 8, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)Pediatrics

Emma Ho, Jordan Fuzi, Gordana Popovic et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the impact of corticosteroid therapy on clinical outcomes in pediatric patients with deep neck space infections (DNSIs). Analyzing data from three studies involving 2523 patients, the results indicated that corticosteroids were associated with a significantly lower rate of surgical intervention, with a relative risk of 2.07 (95% CI: 1.43 - 2.99) for surgery when corticosteroids were not used.

Key findings

  • Corticosteroids were used with antibiotics in 695 patients and without in 1828 patients.
  • The rate of surgical intervention was significantly higher without corticosteroids, with a relative risk of 2.07.
  • Moderate heterogeneity was observed between studies (I² = 58.8%, p = 0.088).

Why it matters

Understanding the role of corticosteroids in managing DNSIs can help clinicians optimize treatment strategies, potentially reducing the need for surgical interventions and improving patient outcomes in this vulnerable population.

Source

PubMed · PMID 42570612

Published in Int J Pediatr Otorhinolaryngol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.